FDA OKs Topical Roflumilast for Psoriasis in Kids Aged 6-11 FDA OKs Topical Roflumilast for Psoriasis in Kids Aged 6-11

This marks an expanded indication for the drug, which was first approved for the same indication in July 2022 for individuals aged 12 and older.MDedge News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Dermatology News Source Type: news